p-quinone mediates 6-hydroxydopamine-induced dopaminergic neuronal death and ferrous iron accelerates the conversion of p-quinone into melanin extracellularly

被引:86
作者
Izumi, Y
Sawada, H
Sakka, N
Yamamoto, N
Kume, T
Katsuki, H
Shimohama, S
Akaike, A
机构
[1] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Neurol, Kyoto 6068501, Japan
关键词
dopamine neuron; ferrous iron; 6-hydroxydopamine; Parkinson's disease; p-quinone;
D O I
10.1002/jnr.20382
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Parkinson's disease (PD) is characterized by the selective loss of dopaminergic neurons in the substantia nigra (SN). 6-Hydroxydopamine (6-OHDA), a dopaminergic neurotoxin, is detected in human brains and the urine of PD patients. Using SH-SY5Y, a human neuroblastoma cell line, we demonstrated that 6-OHDA toxicity was determined by the amount of p-quinone produced in 6-OHDA auto-oxidation rather than by reactive oxygen species (ROS). Glutathione (GSH), which conjugated with p-quinone, provided significant protection whereas catalase, which detoxified hydrogen peroxide and superoxide anions, failed to block cell death caused by 6-OHDA. Although iron accumulated in the SN of patients with PD can cause dopaminergic neuronal degeneration by enhancing oxidative stress, we found that extracellular ferrous iron promoted the formation of melanin and reduced the amount of p-quinone. The addition of ferrous iron to the culture medium inhibited caspase-3 activation and apoptotic nuclear morphologic changes and blocked 6-OHDA-induced cytotoxicity in SH-SY5Y cells and primary cultured mesencephalic dopaminergic neurons. These data suggested that generation of p-quinone played a pivotal role in 6-OHDA-induced toxicity and extracellular iron in contrast to intracellular iron was protective rather than harmful because it accelerated the conversion of p-quinone into melanin. (C) 2005 Wiley-Liss, Inc.
引用
收藏
页码:849 / 860
页数:12
相关论文
共 43 条
  • [1] THE DETERMINATION OF HYDROXYDOPAMINES AND OTHER TRACE AMINES IN THE URINE OF PARKINSONIAN-PATIENTS AND NORMAL CONTROLS
    ANDREW, R
    WATSON, DG
    BEST, SA
    MIDGLEY, JM
    WENLONG, H
    PETTY, RKH
    [J]. NEUROCHEMICAL RESEARCH, 1993, 18 (11) : 1175 - 1177
  • [2] Reaction of oxygen with 6-hydroxydopamine catalyzed by Cu, Fe, Mn, and V complexes: Identification of a thermodynamic window for effective metal catalysis
    Bandy, B
    Walter, PB
    Moon, J
    Davison, AJ
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2001, 389 (01) : 22 - 30
  • [3] Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats
    Ben Shachar, D
    Kahana, N
    Kampel, V
    Warshawsky, A
    Youdim, MBH
    [J]. NEUROPHARMACOLOGY, 2004, 46 (02) : 254 - 263
  • [4] THE IRON CHELATOR DESFERRIOXAMINE (DESFERAL) RETARDS 6-HYDROXYDOPAMINE-INDUCED DEGENERATION OF NIGROSTRIATAL DOPAMINE NEURONS
    BENSHACHAR, D
    ESHEL, G
    FINBERG, JPM
    YOUDIM, MBH
    [J]. JOURNAL OF NEUROCHEMISTRY, 1991, 56 (04) : 1441 - 1444
  • [5] Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: Implications for Parkinson's disease
    Berman, SB
    Hastings, TG
    [J]. JOURNAL OF NEUROCHEMISTRY, 1999, 73 (03) : 1127 - 1137
  • [6] Chen SY, 2000, J PHARMACOL EXP THER, V294, P134
  • [7] Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.3.CO
  • [8] 2-5
  • [9] The cytotoxicity of dopamine may be an artefact of cell culture
    Clement, MW
    Long, LH
    Ramalingam, J
    Halliwell, B
    [J]. JOURNAL OF NEUROCHEMISTRY, 2002, 81 (03) : 414 - 421
  • [10] Coelln RV, 2001, J NEUROCHEM, V77, P263